Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Livial TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: tibolone
Brand name
(ARTG)
: LIVIAL tibolone 2.5mg tablet blister packDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
Short-term treatment of symptoms resulting from the natural or surgical menopause in post menopausal women. Second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. After careful selection of users, Livial should be prescribed for the shortest duration consistent with treatment goals. Review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer Clinical Trials and Precautions). Livial should only be continued for as long as the benefit outweighs the risks.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Tablet, uncoated
- Oral
- 6mm diameter white, round, flat tablets with bevelled edge coded "MK" above "2" on one side and "Organon" and a star on the other.
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Protect from Light
- Protect from Moisture
- Shelf lifetime is 2 Years.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 10 tablets Starter Pack pack
- 28 tablets pack
- 84 tablets pack
Over 65 ?
(AHT)
This medicine contains the active ingredients:
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient tibolone
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Need more information?
These trusted information partners have more on this topic.
Top results
Vaginal health after breast cancer: A guide for patients - Australasian Menopause Society
Women who have had breast cancer treatment before menopause might find they develop symptoms such as hot flushes, night sweats, joint aches and vaginal dryness. These are symptoms of low oestrogen, which occur naturally with age, but may also occur in younger women undergoing treatment for breast cancer. These changes are called the genito-urinary syndrome of menopause (GSM), which was previously known as atrophic vaginitis.
Read more on Australasian Menopause Society website
Top results
Tibolone as menopausal hormone therapy - Australasian Menopause Society
Tibolone is a synthetic steroid molecule which is, in essence, a progestogen. Post absorption, its metabolites have oestrogenic, progestogenic and androgenic properties
Read more on Australasian Menopause Society website
AMS Guide to Equivalent MHT/HRT Doses Australia only - Australasian Menopause Society
Information Sheet has been developed as a guideline only to approximately equivalent doses of the different MHT/HRT products available in Australia.
Read more on Australasian Menopause Society website
Osteoporosis - Australasian Menopause Society
Osteoporosis is a condition characterised by weakened bones that fracture easily. After menopause many women are at risk of developing osteoporosis. Peak bone mass is usually reached during a woman’s 20s to 30s when the skeleton has stopped growing and bones are at their strongest. The female sex hormone oestrogen plays an important role in maintaining bone strength. After menopause oestrogen levels drop and this may result in increased bone loss. The average woman loses up to 10 per cent of
Read more on Australasian Menopause Society website
